Insider Selling: CareDx, Inc (NASDAQ:CDNA) Director Sells 5,000 Shares of Stock

CareDx, Inc (NASDAQ:CDNA) Director Peter Maag sold 5,000 shares of the firm’s stock in a transaction that occurred on Tuesday, November 26th. The stock was sold at an average price of $25.00, for a total transaction of $125,000.00. Following the sale, the director now owns 330,024 shares in the company, valued at approximately $8,250,600. This trade represents a 1.49 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink.

CareDx Stock Performance

Shares of CDNA stock traded down $0.68 during trading hours on Tuesday, hitting $24.96. 548,186 shares of the company were exchanged, compared to its average volume of 795,245. The business’s 50-day simple moving average is $25.51 and its two-hundred day simple moving average is $22.67. CareDx, Inc has a one year low of $7.42 and a one year high of $34.84.

CareDx (NASDAQ:CDNA) last posted its earnings results on Monday, November 4th. The company reported ($0.14) EPS for the quarter, topping the consensus estimate of ($0.25) by $0.11. The firm had revenue of $82.88 million during the quarter, compared to analysts’ expectations of $80.04 million. CareDx had a negative net margin of 45.90% and a negative return on equity of 53.70%. CareDx’s quarterly revenue was up 23.4% on a year-over-year basis. During the same quarter in the prior year, the firm earned ($0.43) EPS. Equities analysts anticipate that CareDx, Inc will post -0.7 earnings per share for the current fiscal year.

Analyst Ratings Changes

CDNA has been the subject of several research reports. HC Wainwright reissued a “neutral” rating on shares of CareDx in a research note on Tuesday, October 22nd. Wells Fargo & Company began coverage on shares of CareDx in a research note on Tuesday, August 27th. They issued an “underweight” rating and a $28.00 target price on the stock. StockNews.com upgraded shares of CareDx from a “hold” rating to a “buy” rating in a report on Thursday, October 17th. The Goldman Sachs Group lifted their price objective on shares of CareDx from $26.00 to $35.00 and gave the company a “buy” rating in a research note on Wednesday, October 16th. Finally, BTIG Research dropped their target price on CareDx from $40.00 to $35.00 and set a “buy” rating on the stock in a research report on Tuesday, November 5th. One analyst has rated the stock with a sell rating, two have given a hold rating and five have assigned a buy rating to the stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $29.60.

Institutional Investors Weigh In On CareDx

A number of hedge funds and other institutional investors have recently modified their holdings of CDNA. Franklin Resources Inc. raised its position in CareDx by 34.4% in the third quarter. Franklin Resources Inc. now owns 59,474 shares of the company’s stock worth $1,862,000 after acquiring an additional 15,238 shares in the last quarter. Virtue Capital Management LLC acquired a new stake in shares of CareDx during the third quarter worth $755,000. Geode Capital Management LLC lifted its holdings in shares of CareDx by 2.7% during the third quarter. Geode Capital Management LLC now owns 1,227,724 shares of the company’s stock valued at $38,343,000 after purchasing an additional 32,141 shares during the last quarter. Barclays PLC boosted its position in shares of CareDx by 123.8% in the 3rd quarter. Barclays PLC now owns 98,505 shares of the company’s stock valued at $3,075,000 after purchasing an additional 54,482 shares during the period. Finally, Main Management ETF Advisors LLC purchased a new position in CareDx in the 3rd quarter worth about $1,405,000.

About CareDx

CareDx, Inc engages in the discovery, development, and commercialization of diagnostic solutions for transplant patients and caregivers in the United States and internationally. It also provides AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for heart transplant patients; and AlloSure Lung, a dd-cfDNA solution for lung transplant patients.